GSK Just Wrote a $10.6 Billion Check for Two Drugs That Don't Exist Yet

Neladalkib targets a different mutation called ALK. It earned FDA Breakthrough Therapy designation, which is the agency's way of saying, "We think this could be a meaningful advance; let's speed things up." Nuvalent reported positive pivotal data from the ALKOVE-1 trial. A Phase 3 trial called ALKAZAR is also underway, pitting neladalkib head-to-head against Roche's alectinib (the current standard of care) in previously untreated patients.

So GSK isn't buying a science project. It's buying two late-stage drugs with real data, FDA timelines measured in months, and a clear path to commercialization. That's rare, and that rarity comes at a premium.

Why GSK Needs This (Badly)

GSK has a problem looming on the horizon: its blockbuster HIV drug dolutegravir is heading toward a patent cliff. When your biggest revenue generator starts facing generic competition, you need something to fill the gap. Fast.

Barclays analyst James Gordon has argued that this acquisition will help offset that cliff by accelerating GSK's entry into lung cancer, one of the largest and fastest-growing markets in oncology. Lung cancer drugs collectively generate tens of billions in annual sales globally, and precision therapies targeting specific mutations like ALK and ROS1 command premium pricing.

GSK has been building toward this moment. In recent years, the company acquired IDRx (a rare cancer biotech) for about $1 billion, licensed antibody-drug conjugates from Hansoh Pharma in a deal worth up to $1.7 billion, and invested in AI-driven oncology discovery through partnerships with companies like Noetik. The Nuvalent deal isn't a random splurge; it's the capstone of a deliberate pivot toward precision oncology.

The plan, eventually, is to combine Nuvalent's targeted therapies with GSK's own B7-H3 antibody-drug conjugate to build a comprehensive thoracic oncology franchise. Think of it like assembling a basketball team: you don't just need a point guard, you need the whole roster working together.

Wall Street Isn't Totally Sold

GSK shares dropped about 3% after the announcement, which tells you something about investor sentiment. The strategic logic makes sense on paper, but the execution risk is real.

Bloomberg Intelligence analyst Javier Manso Polo noted that the $10.6 billion price tag "allows little margin for error." That's analyst-speak for: this better work. UBS analysts pointed out that the deal is unusually large for GSK, which has historically preferred bolt-on acquisitions in the $2–4 billion range. Jumping to $10.6 billion is like going from ordering appetizers to buying the entire restaurant.

AJ Bell's Russ Mould called the investor caution "understandable," noting that both headline drugs still need regulatory approval and that integrating a fast-moving U.S. biotech into a large pharma structure is never simple. GSK itself acknowledges the deal will cause low single-digit EPS dilution from 2026 through 2028 before becoming accretive in 2029.

The average analyst rating on GSK? Still a "Hold."

The Competitive Battlefield Ahead

Even if both drugs get approved, Nuvalent's therapies won't waltz into an empty market. Pfizer's lorlatinib (Lorbrena) is already entrenched in ALK-positive lung cancer, particularly in later lines of treatment. Roche's alectinib (Alecensa) remains the frontline standard for ALK-positive patients, while its entrectinib (Rozlytrek) competes in the ROS1 space.

What Nuvalent's drugs offer, at least in theory, is better brain penetration and improved coverage of resistance mutations (the genetic workarounds that tumors develop to dodge existing drugs). In a disease where brain metastases are devastatingly common, that could be a genuine differentiator. But "could be" and "proven to be" are separated by years of clinical data and commercial execution.

Newer competitors like repotrectinib are also entering the ROS1 market with strong activity data, meaning Nuvalent won't just be fighting the old guard.

The Bottom Line

GSK is making the kind of bet that either defines a company's next decade or becomes a cautionary tale in future MBA case studies. The assets are real, the data is promising, and the strategic need is clear. But at $10.6 billion with two unapproved drugs, a looming patent cliff, and fierce competition in lung cancer, the margin for stumbles is razor-thin.

The first real test arrives September 18, when the FDA is expected to rule on zidesamtinib. If that goes well, this deal starts looking like a masterstroke. If it doesn't, GSK will have a very expensive problem on its hands.

No pressure.

The Insulin That Kids Don't Have to Stab Themselves With

Inhaled insulin flopped spectacularly with adults. Now MannKind's Afrezza just became the first needle-free mealtime insulin approved for kids, targeting a population where needle fear isn't just annoying — it's clinically dangerous.